共 145 条
[1]
Levine DP(2006)Vancomycin: a history Clinical infectious diseases. 42 S5-S12
[2]
Liu C(2011)Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 e18-e55
[3]
Bayer A(2006)Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care–associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices Chest 130 947-955
[4]
Cosgrove SE(2020)Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 77 835-864
[5]
Daum RS(2011)Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients Ann Pharmacother 45 582-589
[6]
Fridkin SK(2009)Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate Pediatr Infect Dis J 28 398-2840
[7]
Gorwitz RJ(2014)Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations Antimicrob Agents Chemother 58 2830-168
[8]
Jeffres MN(2014)Achieving therapeutic vancomycin levels in pediatric patients Can J Hosp Pharm 67 416-72
[9]
Isakow W(2009)Evaluating the empiric dose of vancomycin in pediatric patients J Pediatr Pharmacol Ther 14 167-281
[10]
Doherty JA(2013)Improved vancomycin dosing in children using area-under-the-curve exposure Pediatr Infect Dis J 32 1264-7